Oncolytics Biotech (ONCY) Cash & Equivalents (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Cash & Equivalents for 17 consecutive years, with $5.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 54.42% year-over-year to $5.2 million; the TTM figure through Dec 2025 stood at $5.2 million (down 54.42% YoY), while the FY2025 annual figure was $5.2 million, down 53.05% from the prior year.
• Cash & Equivalents slipped to $5.2 million in Q4 2025 per ONCY's latest filing, from $9.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $41.3 million in Q2 2021 and bottomed at $5.2 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $21.2 million across 5 years, with a median of $20.1 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 73.75% — and 2023, when it jumped 198.38%.
• Oncolytics Biotech's Cash & Equivalents stood at $32.7 million in 2021, then tumbled by 73.75% to $8.6 million in 2022, then surged by 198.38% to $25.6 million in 2023, then sank by 55.5% to $11.4 million in 2024, then slumped by 54.42% to $5.2 million in 2025.
• Business Quant data shows ONCY's Cash & Equivalents at $5.2 million in Q4 2025, $9.0 million in Q3 2025, and $10.6 million in Q2 2025.